Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 June;48(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 June;48(2):109-18

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

  NUCLEAR MEDICINE AND ONCOLOGY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 June;48(2):109-18

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Position of nuclear medicine modalities in the diagnostic work-up of breast cancer

Buscombe J. R. 1, Holloway B. 1, Roche N. 1, Bombardieri E. 2

1 Royal Free Hospital, London, UK 2 Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy


PDF


Breast ­tumors can be ­imaged by dif­fer­ent modal­ities: mam­mog­ra­phy is the ­most wide­ly ­used tech­nique ­because of its diag­nos­tic val­ue, ­patient com­pli­ance and low ­costs. Some tech­niques ­such as ultra­sound (US) are ­often indi­cat­ed, ­while oth­ers, ­such as dig­i­tal mam­mog­ra­phy and mag­net­ic res­o­nance imag­ing (MRI) are ­still ­under eval­u­a­tion and ­seem to be ­very prom­is­ing. Among the nucle­ar med­i­cine tech­niques ­breast scin­tig­ra­phy ­with 99mTc-­labelled lip­o­phil­ic cat­ions (SestaMIBI or tet­ro­fos­min), posi­tron emis­sion tomog­ra­phy (PET) ­with 18F-2-­deoxy-2-flu­o­ro-D-glu­cose (FDG) ­have ­been eval­u­at­ed in ­many clin­i­cal ­trials. At ­present ­breast scin­tig­ra­phy has lim­it­ed appli­ca­tions due to its ­poor spa­tial res­o­lu­tion, ­which has a min­i­mum of 8 mm. It is ques­tion­able wheth­er sin­gle pho­ton emis­sion tomog­ra­phy (SPECT) can ­offer any sub­stan­tial­ly bet­ter infor­ma­tion on the ­breast; how­ev­er, ­SPECT is ­more accu­rate in detect­ing axil­lary ­lymph ­nodes. Recent approach­es ­using ­breast ded­i­cat­ed col­li­ma­tors and cam­e­ras ­have great­ly ­improved the ­SPECT res­o­lu­tion and sen­si­tiv­ity. The ­most inter­est­ing tech­nique ­offered by nucle­ar med­i­cine ­today are PET and lym­phos­cin­tig­ra­phy ­with the intra­op­er­a­tive detec­tion of han­dled γ ­probe. The sen­ti­nel ­node detec­tion has ­achieved a ­large con­sen­sus of reli­abil­ity and at ­present it has an impor­tant ­place in the clin­i­cal man­age­ment. In the ­same ­time ­many ­authors ­have acknowl­edged the val­ue of PET in the dif­fe­ren­tial diag­no­sis of ­breast ­lesions and in loco­re­gion­al stag­ing, ­since ­breast can­cer is strong­ly ­avid for glu­cose. PET dem­on­strat­ed ­also its effi­ca­cy in detect­ing axil­lary ­lymph ­node metas­ta­ses. Even in ­some clin­i­cal ­trials its accu­ra­cy ­proved near­ly com­par­able to ­that of lym­phos­cin­tig­ra­phy ­with sen­ti­nel ­node biop­sy, oth­er stud­ies ­showed ­that PET scan­ning ­does not cur­rent­ly ­have ade­quate spa­tial res­o­lu­tion to ­detect ­both ­micro- and ­small mac­ro­met­a­stat­ic dis­ease in axil­lary ­lymph ­nodes. The add­ed val­ue of PET in ­breast can­cer stag­ing is ­that ­with a sin­gle exam­ina­tion PET ­allows the char­ac­ter­isa­tion of ­breast ­lesions, in addi­tion to com­plete view­ing of the ­entire ­body. Whole-­body PET may sub­sti­tute oth­er diag­nos­tic assess­ments by exam­in­ing the var­i­ous ­regions of poten­tial ­tumour ­spread. The cur­rent diag­nos­tic ­work-up for pre- and ­postoper­a­tive stag­ing ­includes var­i­ous exam­ina­tions: ­chest X-­rays, US of the abdo­men, mam­mog­ra­phy of the con­tra­lat­er­al ­breast. Bone scin­tig­ra­phy ­with 99mTc-diphos­pho­nates and labor­a­to­ry ­tests can ­also be con­sid­ered in wom­en ­with ­large ­tumors or in symp­to­mat­ic ­patients. Computed tomog­ra­phy (CT) and MRI may be ­used in ­order to ­resolve par­tic­u­lar diag­nos­tic prob­lems. The cur­rent appli­ca­tion of ­some of ­these modal­ities ­depends on the ­risk of the sin­gle ­patient of devel­op­ing met­a­stat­ic ­spread, ­which is ­revealed by a num­ber of prog­nos­tic param­e­ters of ­tumor aggres­sive­ness and of ­course, clin­i­cal ­stage. Bone scin­tig­ra­phy and PET may be use­ful in mon­i­tor­ing ther­a­py ­response and in detect­ing ­tumour relaps­es dur­ing fol­low-up. In par­tic­u­lar PET guid­ed by ­tumor mark­ers meas­ure­ments ­shows to ­detect ­more ­lesions ­than oth­er non nucle­ar med­i­cine modal­ities.

inizio pagina